Make an Inquiry
Accelerating Leber Hereditary Optic Neuropathy Drug Development

Leber hereditary optic neuropathy (LHON) presents a significant therapeutic challenge due to its genetic complexity and rapid progression leading to vision loss. Protheragen specializes in advancing preclinical drug development for LHON, offering a dedicated partnership to translate innovative science into effective therapeutics. Our comprehensive preclinical solutions encompass the full spectrum from target validation and lead optimization to IND-enabling studies, ensuring a seamless transition toward clinical development. Protheragen’s scientific team combines deep expertise in mitochondrial disorders with access to advanced in vitro and in vivo platforms tailored for LHON research. Our rigorous approach integrates state-of-the-art molecular, cellular, and animal models to generate robust, translatable data. With a strong emphasis on regulatory compliance, Protheragen aligns all activities with current industry standards and global regulatory expectations, minimizing risk and expediting program milestones. By leveraging our specialized knowledge and cutting-edge technologies, Protheragen is committed to accelerating the development of novel LHON therapeutics. We enable our partners to overcome the unique challenges of this rare disease, driving progress toward meaningful clinical outcomes and improved patient lives.

What is Leber Hereditary Optic NeuropathyTargets for Leber Hereditary Optic NeuropathyDrug Discovery and Development ServicesWhy Choose Us

What is Leber Hereditary Optic Neuropathy

Leber hereditary optic neuropathy (LHON) is a maternally inherited mitochondrial disorder characterized by acute or subacute, painless loss of central vision, primarily affecting young adult males. The condition arises from point mutations in mitochondrial DNA, most commonly in genes encoding subunits of complex I (NADH dehydrogenase) of the mitochondrial respiratory chain. These mutations disrupt oxidative phosphorylation, resulting in decreased ATP production and increased oxidative stress, which selectively damage retinal ganglion cells and lead to optic nerve atrophy. The three principal mutations—11778 (MT-ND4), 3460 (MT-ND1), and 14484 (MT-ND6)—account for over 90% of cases, with the 11778 mutation being the most prevalent worldwide. Clinically, LHON presents with rapid, bilateral central vision loss, often preceded by mild blurring or color vision deficits. Ophthalmologic examination reveals characteristic findings such as circumpapillary telangiectatic microangiopathy and eventual optic disc atrophy. Diagnosis is confirmed through molecular genetic testing for the pathogenic mtDNA mutations. Additional assessments, including visual field testing and optical coherence tomography, support the diagnosis and monitor disease progression. Idebenone, a synthetic coenzyme Q10 analog, is an approved treatment that may improve or stabilize vision if initiated early. Early recognition and intervention are essential, as visual loss is typically irreversible, significantly impacting quality of life.

Launched Drugs

Structure Generic Name CAS Registry Number Molecular Formula Molecular Weight
img-58186-27-9-idebenone-rec-inn-usan idebenone (Rec INN; USAN) 58186-27-9 C19 H30 O5 338.439

Learn More

Targets for Leber Hereditary Optic Neuropathy

Targets in Clinical or Later Phases of Development

Target Name Gene Symbol
Calcium channel (nonspecified subtype)
intercellular adhesion molecule 1 ICAM1
cyclin D1 CCND1
AP-1 Transcription Factor Complex
DNA methyltransferase 1 DNMT1
epidermal growth factor receptor EGFR
glucose-6-phosphatase catalytic subunit 1 G6PC1
Histone acetyltransferase (HAT) (nonspecified subtype)
Lipoxygenase (nonspecified subtype)
Nuclear factor kappa-light-chain-enhancer of activated B cells

Leber hereditary optic neuropathy (LHON) is primarily driven by mitochondrial dysfunction, leading to increased oxidative stress and subsequent degeneration of retinal ganglion cells. Two key molecular targets implicated in this process are Glutathione-Disulfide Reductase (GSR) and NADPH Oxidase 3 (NOX3). GSR is a crucial mitochondrial enzyme responsible for maintaining redox balance by regenerating reduced glutathione (GSH), the cell’s major antioxidant. Impaired GSR activity results in glutathione depletion, rendering retinal ganglion cells more vulnerable to reactive oxygen species (ROS). NOX3, a member of the NADPH oxidase family, catalyzes the production of superoxide, further contributing to oxidative stress. Although NOX3 is predominantly expressed in the inner ear, related NOX enzymes are upregulated in LHON, amplifying ROS generation and neuronal injury. Targeting these pathways offers promising therapeutic opportunities for LHON. Antioxidant strategies, such as idebenone, aim to restore redox balance by supporting GSR function and mitigating oxidative damage. While no direct GSR-targeting drugs are currently approved, GSR activity serves as a valuable biomarker for disease progression. Similarly, inhibition of NOX enzymes has shown neuroprotective effects in preclinical models, and pan-NOX inhibitors are under investigation. These approaches focus on preserving retinal ganglion cell viability and slowing visual loss, representing rational points for future drug development in LHON.

Learn More

Drug Discovery and Development Services

In Vitro Efficacy Testing ServicesIn Vivo Model DevelopmentPK/PD Study ServicesIn Vivo Toxicity Assessment ServicesBiomarker Analysis Services
In Vitro Efficacy Testing Services

Online Inquiry

Our In Vitro Efficacy Testing Service accelerates Leber hereditary optic neuropathy (LHON) drug discovery through robust, disease-relevant cellular and biochemical assays. We specialize in evaluating mitochondrial function, oxidative stress, and neuroprotection using advanced methods such as chemiluminescent, fluorescent, ELISA, and RNA assays. Key targets include Cyclin D1, DNMT1, EGFR, ICAM-1, COX-1, and COX-2. We provide precise measurement of critical pharmacological parameters including IC-50, MIC, MEC, and MED, enabling rapid, data-driven assessment of candidate therapies. Our service delivers actionable insights for lead optimization and preclinical decision-making in LHON therapeutic development.

Cyclin D1 Dna Methyltransferase 1
Epidermal Growth Factor Receptor Intercellular Adhesion Molecule 1
Prostaglandin-Endoperoxide Synthase 1 Prostaglandin-Endoperoxide Synthase 2

Learn More

Why Choose Us

Choosing Protheragen for your Leber hereditary optic neuropathy drug development needs means partnering with a team deeply committed to advancing therapies in this challenging field. Protheragen brings specialized expertise in Leber hereditary optic neuropathy research, supported by years of focused experience and a thorough understanding of the disease’s unique complexities. Our professional teams are equipped with advanced technology platforms that enable us to deliver innovative solutions and accelerate the drug development process. Protheragen has established a strong track record of reliability in preclinical drug development services, consistently meeting project milestones and exceeding client expectations. We adhere to the highest quality standards and maintain strict regulatory compliance throughout every stage of our work, ensuring that all projects are conducted with integrity and precision. Above all, Protheragen is dedicated to making a meaningful impact on the future of Leber hereditary optic neuropathy therapeutics, working tirelessly to bring new hope to patients and families affected by this condition. Trust Protheragen to be your partner in achieving success in preclinical drug development for Leber hereditary optic neuropathy.

FAQs for Our Services

Q: What are the main preclinical research challenges specific to developing drugs for Leber hereditary optic neuropathy (LHON)?

A: LHON presents unique preclinical challenges due to its mitochondrial genetic basis and the limited availability of relevant animal models. The disease's rarity and heterogeneity, as well as the difficulty in replicating human mitochondrial mutations in preclinical systems, complicate efficacy and safety assessments. Our company addresses these challenges by leveraging advanced in vitro models, such as patient-derived induced pluripotent stem cells (iPSCs) and retinal organoids, as well as collaborating with academic partners to access and develop suitable in vivo models.

Q: What are the key regulatory considerations when developing drugs for LHON?

A: Given that LHON is a rare genetic disorder, drug development often qualifies for orphan drug designation, which can provide regulatory incentives. However, regulators require robust preclinical data demonstrating safety, mechanism of action, and potential efficacy, particularly due to the involvement of mitochondrial pathways. Our team is experienced in designing preclinical studies that comply with FDA and EMA guidelines, ensuring comprehensive toxicology, pharmacokinetics, and proof-of-concept data packages tailored for rare ophthalmic diseases.

Q: What technical aspects are most important in preclinical LHON research?

A: Technical priorities include developing reliable cellular and animal models that recapitulate LHON pathology, establishing sensitive assays to measure mitochondrial function, and quantifying optic nerve and retinal ganglion cell health. Our laboratories utilize state-of-the-art technologies such as high-content imaging, mitochondrial bioenergetics assays, and CRISPR-based gene editing to generate disease-relevant models and endpoints that support translational research.

Q: What are the typical timeline and cost considerations for preclinical LHON drug development?

A: Preclinical development for LHON therapeutics typically spans 18–36 months, depending on the complexity of the candidate and required studies. Costs can vary significantly, generally ranging from $2 million to $6 million for comprehensive preclinical packages. Our company offers modular service options and efficient project management to optimize timelines and control costs, while ensuring high-quality data generation to support regulatory submissions.

Q: What are the key success factors in preclinical drug development for LHON?

A: Success in LHON preclinical development relies on selecting appropriate disease models, generating robust efficacy and safety data, and maintaining close alignment with regulatory requirements. Early engagement with regulatory agencies, integration of biomarker strategies, and leveraging patient-derived materials are also critical. Our multidisciplinary team provides end-to-end support, from model selection to IND-enabling studies, to maximize the likelihood of clinical and regulatory success.

Make an Inquiry
Important Links
Get in Touch with Us

Copyright © 2025 Protheragen. All rights reserved.